This database contains 16 studies, archived under the term: "BMC Neurology"
Click here to filter this large number of results.
V-TIME: a treadmill training program augmented by virtual reality to decrease fall risk in older adults: study design of a randomized controlled trial
Mirelman, Anat,
Rochester, Lynn,
Reelick, Miriam,
Nieuwhof, Freek,
Pelosin, Elisa,
Abbruzzese, Giovanni,
Dockx, Kim,
Nieuwboer, Alice,
Hausdorff, Jeffrey M.
Background: Recent work has demonstrated that fall risk can be attributed to cognitive as well as motor deficits. Indeed, everyday walking in complex environments utilizes executive function, dual tasking, planning and scanning, all while walking forward. Pilot studies suggest that a multi-modal intervention that combines treadmill training to target motor function and a virtual reality […]
Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
Background: A varying response to cholinesterase inhibitor (ChEI) treatment has been reported among patients with Alzheimer’s disease (AD). Whether the individual-specific response, specific ChEI agent or dose affects mortality is unclear. We aimed to examine the relationship between the 6-month response to ChEI and lifespan. Methods: Six hundred and eighty-one deceased patients with a clinical […]
Physical activity program for patients with dementia and their relative caregivers: randomized clinical trial in Primary Health Care (AFISDEMyF study)
Rodriguez-Sánchez, Emiliano,
Criado-Gutiérrez, José,
Mora-Simón, Sara,
Muriel-Diaz, M,
Gómez-Marcos, Manuel A,
Recio-Rodríguez, José I,
Patino-Alonso, M,
Valero-Juan, Luis F,
Maderuelo-Fernandez, José A,
García-Ortiz, Luis
Background: The aging of the population has led to the increase of chronic diseases, especially dementia and cardiovascular diseases, and it has become necessary for their relatives to dedicate more time in caregiving.The objective in the first phase of this study is to evaluate the effectiveness of a Primary Health Care procedure to increase the […]
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
Burstein, Aaron H,
Grimes, Imogene,
Galasko, Douglas R,
Aisen, Paul S,
Sabbagh, Marwan,
Mjalli, Adnan MM
Background: TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive […]